ResultsIQ

ResultsIQ › Latest results › Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited Q3 FY26 results press release summary

NSE: SOLARA · BSE: 541540

Results press release of 6 Feb 2026, summarised by AI from the filing.

Solara Q3'26 revenue ₹3,490 mn, up 15% YoY, led by growth APIs; Ibuprofen base remains a drag.

Key takeaways

  1. Q3'26 revenue Revenue ₹3,490 mn, up 15% YoY and 10% QoQ, led by growth APIs.
  2. Strategic review Board appointing advisors to evaluate Ibuprofen options and re-assess CRAMS split scheme; roadmap next quarter.
  3. Ibuprofen drag Commodity Ibuprofen API remains a persistent drag with global oversupply and pricing pressure.

Original filing on BSE

Solara Active Pharma Sciences Limited Q1 FY27 results

As filed: Revenue ₹382 cr (+20% year on year), EBITDA ₹62.0 cr (+7% year on year), PAT ₹16.3 cr (+48% year on year), EBITDA margin 16.2% (−194 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹387 cr (+42% year on year), EBITDA ₹57.7 cr (+28% year on year), PAT ₹9.6 cr, EBITDA margin 14.9% (−160 bps). Score 62 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it. EBITDA margin fell 160 bps year on year. Other income 49% of PBT. Tax rate 0%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +19.9% in 28 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹349 cr (+16% year on year), EBITDA ₹37.3 cr (−37% year on year), PAT −₹17.4 cr (−234% year on year), EBITDA margin 10.7% (−897 bps). Score 20 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it. EBITDA margin fell 897 bps year on year. Share price after the results: −12.8% in 28 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹314 cr (−10% year on year), EBITDA ₹35.0 cr (−43% year on year), PAT −₹10.0 cr (−225% year on year), EBITDA margin 11.2% (−643 bps). Score 20 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend. EBITDA margin fell 643 bps year on year. Profit fell 191% from last quarter. Share price after the results: −10.6% in 30 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹319 cr (−12% year on year), EBITDA ₹58.0 cr (+38% year on year), PAT ₹11.0 cr, EBITDA margin 18.2% (+661 bps). Score 42 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 661 bps year on year. Tax rate 0%. Share price after the results: −3.9% in 28 days (Nifty 500: −1.3%).
  • Q4 FY25: Revenue ₹273 cr (−9% year on year), EBITDA ₹45.0 cr (+300% year on year), PAT −₹2.0 cr, EBITDA margin 16.5% (+1,000 bps). Score 45 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was well above it. EBITDA margin rose 1000 bps year on year. Revenue fell 9% from last quarter. Share price after the results: −12.2% in 29 days (Nifty 500: +1.8%).
  • Q3 FY25: Revenue ₹300 cr (+20% year on year), EBITDA ₹59.0 cr, PAT ₹8.0 cr, EBITDA margin 19.7% (+1,000 bps). Score 73 of 100, Above trend. Revenue growth was well above the company's own trend. EBITDA margin rose 1000 bps year on year. Tax rate 0%. Revenue fell 14% from last quarter.
  • Q2 FY25: Revenue ₹347 cr (−18% year on year), EBITDA ₹61.0 cr (+65% year on year), PAT ₹8.0 cr, EBITDA margin 17.6% (+887 bps). Score 50 of 100, In line with trend. EBITDA margin rose 887 bps year on year. Tax rate 0%. Not enough history for a trend yet: scored on growth alone. Revenue fell 4% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Solara Active Pharma Sciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.